ZA201905645B - Synthesis of mcl-1 inhibitor - Google Patents
Synthesis of mcl-1 inhibitorInfo
- Publication number
- ZA201905645B ZA201905645B ZA2019/05645A ZA201905645A ZA201905645B ZA 201905645 B ZA201905645 B ZA 201905645B ZA 2019/05645 A ZA2019/05645 A ZA 2019/05645A ZA 201905645 A ZA201905645 A ZA 201905645A ZA 201905645 B ZA201905645 B ZA 201905645B
- Authority
- ZA
- South Africa
- Prior art keywords
- mcl
- inhibitor
- synthesis
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Lubricants (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479493P | 2017-03-31 | 2017-03-31 | |
| PCT/EP2018/058056 WO2018178227A1 (en) | 2017-03-31 | 2018-03-29 | Synthesis of mcl-1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201905645B true ZA201905645B (en) | 2020-05-27 |
Family
ID=61827753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/05645A ZA201905645B (en) | 2017-03-31 | 2019-08-27 | Synthesis of mcl-1 inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11149024B2 (https=) |
| EP (1) | EP3601230B1 (https=) |
| JP (1) | JP7032428B2 (https=) |
| KR (1) | KR102604876B1 (https=) |
| CN (1) | CN110536884B (https=) |
| AR (1) | AR111304A1 (https=) |
| AU (1) | AU2018244180B2 (https=) |
| CA (1) | CA3056712A1 (https=) |
| CO (1) | CO2019010035A2 (https=) |
| EA (1) | EA038226B1 (https=) |
| ES (1) | ES2909751T3 (https=) |
| IL (1) | IL269410B2 (https=) |
| MX (1) | MX387814B (https=) |
| TW (1) | TWI781996B (https=) |
| WO (1) | WO2018178227A1 (https=) |
| ZA (1) | ZA201905645B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3781570A4 (en) * | 2018-11-22 | 2021-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | MACROCYCLIC INDOLES SERVING AS MCL-1 INHIBITORS |
| WO2020151738A1 (en) * | 2019-01-23 | 2020-07-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| MA56505A (fr) | 2019-06-21 | 2022-04-27 | Janssen Pharmaceutica Nv | Inhibiteurs macrocycliques de mcl-1 |
| KR20220034136A (ko) | 2019-07-09 | 2022-03-17 | 얀센 파마슈티카 엔.브이. | Mcl-1 억제제로서의 거대환식 스피로사이클 유도체 |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| EP4061819A1 (en) | 2019-11-21 | 2022-09-28 | Janssen Pharmaceutica NV | Macrocyclic indole derivatives as mcl-1 inhibitors |
| WO2021099580A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| EP4107161A1 (en) | 2020-02-21 | 2022-12-28 | Janssen Pharmaceutica NV | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| JP2023526985A (ja) | 2020-05-29 | 2023-06-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状７－ピラゾール－５－イル－インドール誘導体 |
| WO2021255258A1 (en) | 2020-06-19 | 2021-12-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| BR112022025674A2 (pt) | 2020-06-19 | 2023-01-17 | Janssen Pharmaceutica Nv | Derivados de 7-(pirazol-5-il)-indol macrocíclico n-ligado como inibidores de mcl-1 |
| BR112023000212A2 (pt) | 2020-07-08 | 2023-01-31 | Janssen Pharmaceutica Nv | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3200758A1 (en) | 2020-12-17 | 2022-06-23 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CN116848126A (zh) | 2021-02-12 | 2023-10-03 | 詹森药业有限公司 | 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症 |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2915811A1 (en) * | 2014-03-04 | 2015-09-09 | Centre Régional de Lutte contre le Cancer - Centre François Baclesse | MCL-1 modulating compounds for cancer treatment |
| US9949965B2 (en) * | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| CN105061315B (zh) * | 2015-08-06 | 2017-10-24 | 大连理工大学 | 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用 |
| ES2791319T3 (es) * | 2016-04-22 | 2020-11-03 | Astrazeneca Ab | Inhibidores de MCL1 macrocíclicos para tratar el cáncer |
| CN106478606B (zh) * | 2016-09-21 | 2019-05-10 | 沈阳药科大学 | N-取代吲哚类衍生物及其应用 |
-
2018
- 2018-03-26 TW TW107110205A patent/TWI781996B/zh active
- 2018-03-28 AR ARP180100757A patent/AR111304A1/es unknown
- 2018-03-29 US US16/497,919 patent/US11149024B2/en active Active
- 2018-03-29 AU AU2018244180A patent/AU2018244180B2/en active Active
- 2018-03-29 WO PCT/EP2018/058056 patent/WO2018178227A1/en not_active Ceased
- 2018-03-29 ES ES18714249T patent/ES2909751T3/es active Active
- 2018-03-29 MX MX2019011468A patent/MX387814B/es unknown
- 2018-03-29 CA CA3056712A patent/CA3056712A1/en active Pending
- 2018-03-29 CN CN201880021146.0A patent/CN110536884B/zh active Active
- 2018-03-29 EP EP18714249.2A patent/EP3601230B1/en active Active
- 2018-03-29 JP JP2019552891A patent/JP7032428B2/ja active Active
- 2018-03-29 EA EA201992235A patent/EA038226B1/ru unknown
- 2018-03-29 KR KR1020197031979A patent/KR102604876B1/ko active Active
-
2019
- 2019-08-27 ZA ZA2019/05645A patent/ZA201905645B/en unknown
- 2019-09-16 CO CONC2019/0010035A patent/CO2019010035A2/es unknown
- 2019-09-17 IL IL269410A patent/IL269410B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI781996B (zh) | 2022-11-01 |
| JP2020515557A (ja) | 2020-05-28 |
| CN110536884A (zh) | 2019-12-03 |
| IL269410B2 (en) | 2023-03-01 |
| KR102604876B1 (ko) | 2023-11-22 |
| BR112019019686A2 (pt) | 2020-04-14 |
| JP7032428B2 (ja) | 2022-03-08 |
| US20210122735A1 (en) | 2021-04-29 |
| US11149024B2 (en) | 2021-10-19 |
| MX2019011468A (es) | 2019-11-01 |
| IL269410B (en) | 2022-11-01 |
| AU2018244180B2 (en) | 2021-03-04 |
| WO2018178227A1 (en) | 2018-10-04 |
| ES2909751T3 (es) | 2022-05-10 |
| EP3601230B1 (en) | 2022-01-26 |
| KR20190136039A (ko) | 2019-12-09 |
| MX387814B (es) | 2025-03-04 |
| CA3056712A1 (en) | 2018-10-04 |
| EA038226B1 (ru) | 2021-07-27 |
| AU2018244180A1 (en) | 2019-11-07 |
| CN110536884B (zh) | 2023-05-02 |
| TW201902868A (zh) | 2019-01-16 |
| EA201992235A1 (ru) | 2020-02-10 |
| IL269410A (en) | 2019-11-28 |
| AR111304A1 (es) | 2019-06-26 |
| CO2019010035A2 (es) | 2019-09-30 |
| EP3601230A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269410B2 (en) | Synthesis of mcl-1 inhibitor | |
| IL291430A (en) | mcl–1 inhibitors | |
| IL270844A (en) | Novel inhibitors of MAP4K1 | |
| IL273230A (en) | Preparation of carbamoylpyridone-polycyclic compounds | |
| PL3645518T3 (pl) | Synteza omekamtywu mekarbilu | |
| ZA201808057B (en) | Synthesis of indazoles | |
| EP3551643A4 (en) | LIRAGLUTIDE SUMMARY | |
| IL262413B (en) | Synthesis of indazoles | |
| ZA201904460B (en) | Inhibitors of nhe-mediated antiport | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| HUE066451T2 (hu) | Mezotrion szintézise | |
| GB201710241D0 (en) | New route of synthesis for opicapone | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| GB201510544D0 (en) | New synthesis of tapentadol-hci intermediates | |
| GB201804905D0 (en) | Cataltic synthesis of biarylic compounds | |
| GB201820685D0 (en) | Synthesis of 8-chloroadenosine derivatives | |
| GB201807468D0 (en) | Methods of synthesis | |
| HK40007680A (en) | N-carboxyanhydride-based-scale synthesis of elamipretide |